ClinicalTrials.gg
Active, not recruitingNCT05248646Updated Jul 14, 2026

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

A Phase 3 interventional study of Sibeprenlimab 400 mg and Placebo in Immunoglobulin A Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 308 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
7th of 67
530 · median 67
Started
2022
with 3 others
Phase 3
21 of 73
8 open now
Primary completion
2026-05
later than 4 of 36 live
Registered
38th of 73
by date
Lead sponsor
5 of 73
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 7th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2022, is one of 21 in phase 3, reaches primary completion later than 4 of the 36 other live ones, and was the 38th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sibeprenlimab 400 mg administered SC Q 4 weeks compared to placebo in patients with IgAN. The primary objective is to compare the relative change from baseline in the urinary protein to creatinine ratio (uPCR) in 24-hour urine collections, after 9 months of treatment. The key secondary objective is to compare the annualized rate of change from baseline (slope) of estimated glomerular filtration rate (eGFR) after approximately 24 months of treatment. There will be one main cohort comprised of approximately 450 subjects with source-verified biopsy-confirmed IgAN and eGFR ≥ 30 mL/min/1.73 m\^2. An additional exploratory cohort will be comprised of up to 20 subjects with source-verified biopsy confirmed IgAN and eGFR of 20 to \< 29 mL/min/1.73 m\^2.

03

Conditions studied

  • Immunoglobulin A Nephropathy

Keywords

  • IgAN
  • Sibeprenlimab
  • VIS649
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥ 18 years of age .
  • -confirmed IgAN. (Patients with an of 30 to 45 mL/min/1.73m2 must have had a kidney biopsy performed within 36 months of the screening visit).
  • Stable and maximally tolerated dose of ACEI and/or ARB for at least 3 months prior to screening. Patients who are on a stable dose of SGLT2i may participate if treatment was initiated ≥3 months prior to screening. Patients who are unable to take an ACEI or ARB may participate if their overall management conforms with standards of care and other protocol requirements.
  • Screening urine protein/creatinine ratio (uPCR) ≥ 0.75 g/g or urine protein ≥ 1.0 g/day
  • eGFR ≥ 30 mL/min/1.73 m2, (for the exploratory cohort only: eGFR 20- \<30 mL/min/1.73 m2), calculated using the 2021 CKD-EPI equation

Exclusion criteria

Exclusion Criteria:

  • Secondary forms of IgAN or IgA vasculitis.
  • Coexisting chronic kidney disease other than IgAN.
  • Kidney findings in addition to IgAN including those of diabetic nephropathy, membranous nephropathy, or lupus nephritis. Hypertensive vascular changes are acceptable.
  • Kidney biopsy MEST or MEST-C score of T2 or C2 (Oxford IgAN classification). If MEST-scoring was not performed, the presence of > 50% tubulo-interstitial fibrosis, or crescents in > 25% of glomeruli is exclusionary. This does not apply to the exploratory cohort.
  • Nephrotic syndrome
  • Serum IgG \< 600 mg/dL at screening.
  • Chronic systemic , including , within 16 weeks of randomization
  • Participation in another interventional clinical trial and receipt of another drug within 30 days prior to the administration of IMP or 5 half-lives from last investigational drug administration, whichever is longer.
  • Chronic infectious disease, or acute infectious disease at time of screening.
  • Type 1 diabetes, or poorly controlled Type 2 diabetes
  • Uncontrolled hypertension

The protocol provides additional information about these and other inclusion and exclusion criteria.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
530 participants (actual)

Study arms

  • Active comparator
    Sibeprenlimab 400 mg s.c. q 4weeks

    Drug: Sibeprenlimab 400 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Solution for Injection

    Also known as: VIS649

  • DrugPlacebo

    Placebo s.c. q 4 weeks

06

What researchers measure

Primary outcomes

  1. Urinary protein to creatinine ratio (uPCR) in a 24-hour collection

    Time frame: At 9 months

Secondary outcomes

  1. Annualized rate of change (slope) of eGFR

    Time frame: Over 24 months

  2. Mean change of eGFR from baseline

    Time frame: Over 24 months

  3. Progression to composite kidney failure (CKF)

    Time frame: Time from the randomization date to first occurrence of CKF

  4. Percentage of participants with Progression to CKF

    Time frame: Over 24 months

  5. Change From Baseline in Total Serum IgA, IgG, and IgM Concentrations

    Time frame: Up to Week 112

  6. Number of Participants With Adverse Events (AEs)

    Time frame: Up to Week 112

  7. Number of Participants With Potentially Clinically Significant Changes in Laboratory Tests

    Time frame: Up to Week 112

  8. Number of Participants With Potentially Clinically Significant Changes in Vital Signs

    Time frame: Up to Week 112

  9. Number of Participants With Potentially Clinically Significant Changes in Physical Examinations

    Time frame: Up to Week 112

  10. Number of Participants With Injection Site Reactions

    Time frame: Up to Week 112

  11. Evaluation of serum ADA

    Time frame: Up to Week 112

07

Study locations

308 sites

Showing the first 100 of 308 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Perkovic V, Barratt J, Lafayette R, Liew A, Suzuki Y, Carroll K, Cheung CK, Tesar V, Trimarchi H, Wong MG, Zhang H, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV. Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial. Kidney Int Rep. 2025 Oct 1;10(12):4207-4218. doi: 10.1016/j.ekir.2025.09.031. eCollection 2025 Dec. PubMed 41426046 ↗
  • Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han SH, Praga M, Chacko B, Sahay M, Cheung CK, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV; VISIONARY Trial Investigators Group. Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. N Engl J Med. 2026 Feb 12;394(7):635-646. doi: 10.1056/NEJMoa2512133. Epub 2025 Nov 8. PubMed 41211929 ↗
  • Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772. PubMed 40465397 ↗

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2026, 49 months.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Feb 21, 2022
StartActual
Mar 15, 2022
Primary completionActual
May 13, 2026
CompletionEst.
Jan 19, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05248646
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Mar 15, 2022
Primary completion
May 13, 2026
Completion
Jan 19, 2027 (estimated)
Last update
Jul 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sibeprenlimab

Start the discussion